Corvus Pharmaceuticals (CRVS) Assets Average: 2022-2025
Historic Assets Average for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $85.0 million.
- Corvus Pharmaceuticals' Assets Average rose 37.74% to $85.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.0 million, marking a year-over-year increase of 37.74%. This contributed to the annual value of $57.2 million for FY2024, which is 0.59% up from last year.
- As of Q3 2025, Corvus Pharmaceuticals' Assets Average stood at $85.0 million, which was up 14.13% from $74.4 million recorded in Q2 2025.
- Corvus Pharmaceuticals' Assets Average's 5-year high stood at $96.9 million during Q2 2022, with a 5-year trough of $42.8 million in Q1 2024.
- Moreover, its 3-year median value for Assets Average was $61.7 million (2024), whereas its average is $60.9 million.
- In the last 5 years, Corvus Pharmaceuticals' Assets Average slumped by 40.03% in 2023 and then skyrocketed by 49.87% in 2025.
- Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Assets Average stood at $74.3 million in 2022, then crashed by 34.39% to $48.7 million in 2023, then skyrocketed by 31.00% to $63.9 million in 2024, then skyrocketed by 37.74% to $85.0 million in 2025.
- Its last three reported values are $85.0 million in Q3 2025, $74.4 million for Q2 2025, and $64.2 million during Q1 2025.